Raymond James & Associates grew its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO) by 6.6% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 199,499 shares of the medical research company’s stock after acquiring an additional 12,439 shares during the period. Raymond James & Associates’ holdings in Thermo Fisher Scientific were worth $37,882,000 as of its most recent SEC filing.
Other hedge funds have also modified their holdings of the company. Icon Wealth Partners LLC purchased a new stake in Thermo Fisher Scientific during the 4th quarter worth $105,000. Bank of Nova Scotia Trust Co. purchased a new stake in Thermo Fisher Scientific during the 3rd quarter worth $106,000. Keeler Thomas Management LLC purchased a new stake in Thermo Fisher Scientific during the 4th quarter worth $106,000. Virtue Capital Management LLC purchased a new stake in Thermo Fisher Scientific during the 4th quarter worth $127,000. Finally, Premia Global Advisors LLC purchased a new stake in Thermo Fisher Scientific during the 4th quarter worth $131,000. 87.67% of the stock is currently owned by institutional investors and hedge funds.
NYSE TMO opened at $205.56 on Friday. Thermo Fisher Scientific Inc. has a one year low of $151.74 and a one year high of $226.44. The company has a quick ratio of 0.92, a current ratio of 1.34 and a debt-to-equity ratio of 0.74. The stock has a market capitalization of $84,101.45, a PE ratio of 21.66, a price-to-earnings-growth ratio of 1.53 and a beta of 1.15.
Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings results on Wednesday, January 31st. The medical research company reported $2.79 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $2.66 by $0.13. Thermo Fisher Scientific had a net margin of 10.64% and a return on equity of 16.01%. The business had revenue of $6.05 billion during the quarter, compared to analyst estimates of $5.72 billion. During the same period in the previous year, the business posted $2.41 EPS. The company’s quarterly revenue was up 22.1% on a year-over-year basis. equities analysts forecast that Thermo Fisher Scientific Inc. will post 10.83 EPS for the current year.
The firm also recently declared a quarterly dividend, which will be paid on Monday, April 16th. Stockholders of record on Thursday, March 15th will be issued a $0.17 dividend. The ex-dividend date of this dividend is Wednesday, March 14th. This is a positive change from Thermo Fisher Scientific’s previous quarterly dividend of $0.15. This represents a $0.68 annualized dividend and a dividend yield of 0.33%. Thermo Fisher Scientific’s payout ratio is 7.17%.
Several equities research analysts recently issued reports on TMO shares. Zacks Investment Research raised shares of Thermo Fisher Scientific from a “hold” rating to a “buy” rating and set a $228.00 price target on the stock in a research note on Tuesday. ValuEngine raised shares of Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a research report on Friday, February 2nd. BTIG Research assumed coverage on shares of Thermo Fisher Scientific in a research report on Friday, January 5th. They issued a “buy” rating and a $230.00 target price for the company. Bank of America boosted their target price on shares of Thermo Fisher Scientific from $235.00 to $250.00 and gave the stock a “buy” rating in a research report on Thursday, February 1st. Finally, Leerink Swann reissued an “outperform” rating and issued a $239.00 target price (up previously from $200.00) on shares of Thermo Fisher Scientific in a research report on Thursday, February 1st. They noted that the move was a valuation call. Two analysts have rated the stock with a hold rating and sixteen have given a buy rating to the company’s stock. Thermo Fisher Scientific presently has a consensus rating of “Buy” and an average target price of $221.43.
In other Thermo Fisher Scientific news, SVP Gregory J. Herrema sold 33,327 shares of the business’s stock in a transaction dated Friday, February 2nd. The shares were sold at an average price of $219.70, for a total transaction of $7,321,941.90. Following the completion of the transaction, the senior vice president now directly owns 60,471 shares of the company’s stock, valued at approximately $13,285,478.70. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Marc N. Casper sold 40,000 shares of the business’s stock in a transaction dated Thursday, March 22nd. The shares were sold at an average price of $210.16, for a total transaction of $8,406,400.00. Following the transaction, the chief executive officer now directly owns 334,622 shares of the company’s stock, valued at $70,324,159.52. The disclosure for this sale can be found here. Insiders sold a total of 88,827 shares of company stock valued at $19,012,672 over the last ninety days. Company insiders own 0.49% of the company’s stock.
COPYRIGHT VIOLATION WARNING: This news story was posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this news story on another publication, it was stolen and reposted in violation of U.S. and international copyright and trademark laws. The legal version of this news story can be accessed at https://www.dispatchtribunal.com/2018/04/07/thermo-fisher-scientific-inc-tmo-shares-bought-by-raymond-james-associates.html.
About Thermo Fisher Scientific
Thermo Fisher Scientific Inc develops, manufactures and sells a range of products. The Company provides analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.
Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.